Please login to the form below

Not currently logged in
Email:
Password:

Sygnature Discovery expands business and bioscience teams

Dr Stephen Young and Dr Stuart Thomson join the drug discovery company

Sygnature Discovery Dr Stephen YoungSygnature Discovery has appointed Dr Stephen Young and Dr Stuart Thomson to its senior business and bioscience teams.

Dr Young (picutred right) takes on the role of vice president of business development at the Nottingham, UK-based pharma and biotech service provider.

He brings experience from Hitgen, a Chinese CRO start-up, where he was vice president of business development responsible for several early research collaborations, and previously held business development positions at Novabiochem, Pharmacia and Protherics.

Dr Young also has experience a medicinal chemist across a range of therapeutic areas having worked at Amgen, MSD, Proteus, Tularik and most recently as head of Vertex's discovery chemistry department in the UK.

Sygnature Dr Stuart ThomsonMeanwhile, Dr Stuart Thomson (pictured left) joins Sygnature Discovery as associate director of bioscience.

He has over 12 years of drug discovery and translational research experience, largely in oncology, and moves to the firm from Coferon.

Prior to joining US biotech Dr Thomson spent 10 years at OSI Pharmaceutical where he supported drug discovery programmes initiated as a result of his work in transnational research studies at the company.

Dr Simon Hurst, founder and chief executive officer of Sygnature Discovery, said: “We are delighted to welcome both Stephen and Stuart.

“Stephen will be focusing on business development in Europe and West Coast USA, working in Paul Clewlow's team.

“Stuart joins our ever-expanding bioscience department which we set up in 2011 and will work closely with Dr John Unitt.”

9th February 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics